Please login to the form below

Not currently logged in
Email:
Password:

Rova-T

This page shows the latest Rova-T news and features for those working in and with pharma, biotech and healthcare.

Strike three for Rova-T has AbbVie cutting its losses

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects. AbbVie has run out of patience on its antibody-drug conjugate Rova-T after yet another failed trial in lung cancer, and ... Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC)

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics